| |
 |
Spending on Meds Hit Record High Last Year
U.S. News & World Report - April 14, 2015
Americans' spending on medicine last year increased at its highest rate in 13 years as new drugs were introduced to the market and others were shifted into generic offerings, and as key elements of President Barack Obama's health care law took effect.
3rd largest Medicaid program didn't spend a dime on Sovaldi due to high cost
BioPharma Dive - April 9, 2015
A new Wall Street Journal analysis of federal Medicaid spending data across the country underscores the combative relationship between payers and Gilead Sciences over the exorbitant price of the biotech's hep C cure Sovaldi.
Healthcare Deals Surge in 2015
Healthcare Financial Management Association - April 6, 2015
The underlying forces driving many ownership changes - including costly requirements for not-for-profit hospitals - show no sign of relenting.
Sanofi Executive: No Need to Discount New Diabetes Drug
Drug Discovery & Development - April 13, 2015
Pierre Chancel, the head of Sanofi’s diabetes division, told Bloomberg News in a phone interview on Monday the French drugmaker will not offer discounts on its new form of insulin called Toujeo.
New combo for cystic fibrosis could be a budget buster
Managed Care - April, 2015
Sovaldi, Harvoni, Viekira Pak, a slew of oncology meds—they’re all contributing to specialty pharmacy sticker shock.
Cheap Allergy Drug May Hold Potential as Hepatitis C Treatment
HealthDay News - April 8, 2015
Preliminary lab research suggests a hay fever drug that costs about 50 cents a pill has the potential to treat hepatitis C, a stubborn disease that has spawned drugs that sell for $1,000 a dose.
Study Warns of Diet Supplement Dangers Kept Quiet by F.D.A.
New York Times - April 7, 2015
Popular weight-loss and workout supplements on sale in hundreds of vitamin shops across the nation contain a chemical nearly identical to amphetamine, the powerful stimulant, and pose dangers to the health of those who take them, according to a new study.
Actavis: No Apologies for Seeking Alzheimer's Drug Profits
Associated Press - April 14, 2015
A lawyer for the Irish manufacturer of an Alzheimer's drug urged a U.S. appeals court on Monday to let it replace a two-pill daily regimen with a single-dose version of the drug even if it cheats generic drugmakers of profits.
Medicare program gets harder to cut
The Hill - April 9, 2015
Medicare Advantage is becoming entrenched and harder to cut as support for the insurance program grows in both parties and enrollment numbers climb.
Walgreens to close 200 U.S. stores
Drug Topics - April 9, 2015
As part of its restructuring plan, Walgreens Boots Alliance announced April 9 that it plans to close about 200 of its less-profitable stores throughout the United States.
AstraZeneca's diabetes drug Onglyza may increase death rate -FDA
Reuters - April 10, 2015
AstraZeneca Plc's diabetes drug Onglyza may be associated with an increased rate of death, according to a preliminary review of data by the U.S. Food and Drug Administration.
Benefit design and the rush, hush, and crush cycles
Milliman - April 9, 2015
Employer health plans have seen significant benefit design changes in the past few years, due to rising healthcare costs and the Affordable Care Act.
Promising developments in tackling resistance to blood cancer drugs
ScienceDaily - April 13, 2015
A drug with the potential to reverse resistance to immunotherapy has been developed by scientists, showing great promise in pre-clinical models.
Contact,
Jan Tankersley
Senior Vice President, Marketing & Sales
Pharmaceutical Strategies Group (PSG)
Office: 972-943-7141
Email: JTankersley@PSGConsults.com
PSGNewsletter@PSGConsults.com
www.PSGConsults.com
 |
 |
 |